Research Analysts Offer Predictions for CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for CRISPR Therapeutics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.48) per share for the quarter, down from their previous estimate of ($1.47). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.70) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.44) EPS.

CRSP has been the subject of a number of other research reports. Barclays dropped their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Wednesday. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Chardan Capital restated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $77.93.

CRISPR Therapeutics Trading Down 1.8 %

CRSP stock opened at $47.78 on Thursday. The stock has a market capitalization of $4.08 billion, a P/E ratio of -16.88 and a beta of 1.62. The firm has a 50-day moving average price of $48.82 and a 200-day moving average price of $51.33. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the business posted ($1.41) earnings per share.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently modified their holdings of CRSP. SFE Investment Counsel grew its position in CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after acquiring an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after acquiring an additional 211 shares during the period. Boston Family Office LLC increased its stake in CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC boosted its position in CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares during the period. Finally, National Bank of Canada FI grew its holdings in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.